The MONARCHE trial showed that abemaciclib, in combination with hormone therapy, demonstrated a significant improvement in disease-free survival in patients with hormone-positive, HER2-negative, node-positive early breast cancer at high risk of early recurrence [31]. This evidence concerns the gene ERBB2 and breast carcinoma.